Cell Source

Cell Source Dividend Coverage

Dividend Coverage Ratio of Cell Source (CLCS) as of Oct 19, 2026.

Dividend Coverage

-

Last updated:

Dividend Coverage Ratio of Cell Source is 2026 - . Dividend Coverage Ratio of Cell Source was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cell Source Stock analysis

What does Cell Source do? Cell Source Inc., based in New York City, operates in the Health Care sector as a biotechnology company specializing in immunotherapy. The company, listed on 14 January 2014, focuses on developing Veto Cell technology, an immune tolerance biotechnology enabling selective immune response blocking. Its lead product targets allogeneic hematopoietic stem cell transplantation, supporting haploidentical transplants with mild conditioning. The pipeline includes VETO CAR-T therapies for B-cell malignancies and solid tumors, as well as Veto Cell applications for kidney and liver transplants and non-malignant disorders. The firm holds a wholly owned subsidiary, Cell Source Limited. Cell Source is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cell Source stock

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio Cell Source since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's Cell Source historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Cell Source

All Key Metrics — Cell Source